{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:13:11Z","timestamp":1778573591322,"version":"3.51.4"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this study was to investigate the causal effect of immune cell phenotype on GBS using two-sample Mendelian randomization (MR) approach.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study used MR to investigate the causal relationship between 731 immune cell phenotypes and GBS. We used Inverse variance weighted, Weighted median, MR Egger, Simple mode, Weighted mode for MR analysis. We also used the Cochran Q test, MR-Egger intercept test, IVW regression and MR-PRESSO, leave-one-out analysis to assess the presence of horizontal pleiotropy, heterogeneity and stability, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our study revealed a causal relationship between 33 immune cell phenotypes and GBS. Twenty immunophenotypes were observed to be associated with GBS as risk factors. For example, CD20 on IgD+ CD38dim in the B cell group (OR\u2009=\u20091.313, 95%CI:1.042\u20131.654, <jats:italic>p<\/jats:italic>\u2009=\u20090.021), CD3 on CD4 Treg in Treg cell group (OR\u2009=\u20091.395, 95%CI:1.069\u20131.819, <jats:italic>p<\/jats:italic>\u2009=\u20090.014), CD3 on TD CD8br in Maturation stages of T cell group (OR\u2009=\u20091.486, 95%CI:1.025\u20132.154, <jats:italic>p<\/jats:italic>\u2009=\u20090.037), CD16 on CD14+ CD16+ monocyte in Monocyte group (OR\u2009=\u20091.285, 95%CI:1.018\u20131.621, <jats:italic>p<\/jats:italic>\u2009=\u20090.035), CD33dim HLA DR+ CD11b\u2009+\u2009%CD33dim HLA DR+ in Myeloid cell group (OR\u2009=\u20091.262, 95%CI:1.020\u20131.561, <jats:italic>p<\/jats:italic>\u2009=\u20090.032), HLA DR+ NK AC in TBNK cell group (OR\u2009=\u20091.568, 95%CI:1.100\u20132.237, <jats:italic>p<\/jats:italic>\u2009=\u20090.013). Thirteen immune phenotypes are associated with GBS as protective factors. For example, CD19 on PB\/PC in the B cell group (OR\u2009=\u20090.577, 95%CI:0.370\u20130.902, <jats:italic>p<\/jats:italic>\u2009=\u20090.016), CD4 Treg AC in Treg cell group (OR\u2009=\u20090.727, 95%CI:0.538\u20130.983, <jats:italic>p<\/jats:italic>\u2009=\u20090.038), CD11c\u2009+\u2009monocyte %monocyte in cDC group (OR\u2009=\u20090.704, 95%CI:0.514\u20130.966, <jats:italic>p<\/jats:italic>\u2009=\u20090.030), CX3CR1 on CD14+ CD16\u2212 monocyte in Monocyte group (OR\u2009=\u20090.717, 95%CI:0.548\u20130.939, <jats:italic>p<\/jats:italic>\u2009=\u20090.016), Mo MDSC AC in Myeloid cell group (OR\u2009=\u20090.763, 95%CI:0.619\u20130.939, <jats:italic>p<\/jats:italic>\u2009=\u20090.011), CD45 on granulocyte in TBNK group (OR\u2009=\u20090.621, 95%CI:0.391\u20130.984, <jats:italic>p<\/jats:italic>\u2009=\u20090.042).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The findings suggest that certain specific immune cell phenotypes, particularly B cell and Treg cell subpopulations, are causally associated with GBS, providing potential targets for the clinical treatment of GBS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1446472","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T05:10:41Z","timestamp":1731388241000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Causal relationship between immune cells and Guillain-Barr\u00e9 syndrome: a Mendelian randomization study"],"prefix":"10.3389","volume":"15","author":[{"given":"Huaiquan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuoshuo","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06916-6","article-title":"Autoreactive T cells target peripheral nerves in Guillain-Barr\u00e9 syndrome","volume":"626","author":"S\u00faken\u00edkov\u00e1","year":"2024","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"100098","DOI":"10.1016\/j.gloepi.2023.100098","article-title":"Incidence of Guillain-Barr\u00e9 syndrome in the world between 1985 and 2020: a systematic review","volume":"5","author":"Wachira","year":"2023","journal-title":"Global Epidemiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"20503121241239538","DOI":"10.1177\/20503121241239538","article-title":"An updated review on Guillain-Barr\u00e9 syndrome: challenges in infection prevention and control in low- and middle-income countries","volume":"12","author":"Khan","year":"2024","journal-title":"SAGE Open Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0044-1785692","article-title":"The sural-sparing pattern in clinical variants and electrophysiological subtypes of Guillain-Barr\u00e9 syndrome","volume":"82","author":"Castro","year":"2024","journal-title":"Arq Neuropsiquiatr"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12974-021-02319-4","article-title":"Global, regional, and national burden of Guillain-Barr\u00e9 syndrome and its underlying causes from 1990 to 2019","volume":"18","author":"Bragazzi","year":"2021","journal-title":"J Neuroinflammation"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1136\/jnnp-2019-322479","article-title":"Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barr\u00e9 syndrome","volume":"91","author":"Koike","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12028-023-01707-3","article-title":"Guidelines for neuroprognostication in adults with Guillain-Barr\u00e9 syndrome","volume":"38","author":"Busl","year":"2023","journal-title":"Neurocrit Care"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e57066","DOI":"10.7759\/cureus.57066","article-title":"Treatment efficacy of plasmapheresis versus intravenous immunoglobulin in Guillain-Barr\u00e9 syndrome management: a systematic review","volume":"16","author":"Savithri Nandeesha","year":"2024","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/1744666x.2016.1193006","article-title":"Guillain-Barr\u00e9 syndrome: causes, immunopathogenic mechanisms and treatment","volume":"12","author":"Jasti","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e000544","DOI":"10.1136\/bmjno-2023-000544","article-title":"Guillain-Barr\u00e9 syndrome and checkpoint inhibitor therapy: insights from pharmacovigilance data","volume":"6","author":"Abrahao","year":"2024","journal-title":"BMJ Neurol Open"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/s0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","article-title":"Complex genetic signatures in immune cells underlie autoimmunity and inform therapy","volume":"52","author":"Orr\u00f9","year":"2020","journal-title":"Nat Genet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jneuroim.2007.09.034","article-title":"Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barr\u00e9 syndrome","volume":"192","author":"Chi","year":"2007","journal-title":"J Neuroimmunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/cei\/uxac084","article-title":"The potential for treg-enhancing therapies in nervous system pathologies","volume":"211","author":"Olson","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.14715\/cmb\/2017.63.10.17","article-title":"Clinical efficacy and mechanism of lymphoplasma exchange in the treatment of Guillain-Barre syndrome","volume":"63","author":"Luo","year":"2017","journal-title":"Cell Mol Biol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1517\/14728222.2016.1086751","article-title":"Are Th17 cells and their cytokines a therapeutic target in Guillain-Barr\u00e9 syndrome?","volume":"20","author":"Wu","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jocn.2007.09.016","article-title":"Increased levels of activated T-cells and reduced levels of CD4\/CD25+ cells in peripheral blood of Guillain-Barr\u00e9 syndrome patients compared to controls","volume":"15","author":"Harness","year":"2008","journal-title":"J Clin Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"577042","DOI":"10.1016\/j.jneuroim.2019.577042","article-title":"Intravenous immunoglobulin promotes the proliferation of CD4(+)CD25(+) Foxp3(+) regulatory T cells and the cytokines secretion in patients with Guillain-Barr\u00e9 syndrome in vitro","volume":"336","author":"Zhang","year":"2019","journal-title":"J Neuroimmunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2215153","DOI":"10.1080\/21645515.2023.2215153","article-title":"Progress in Guillain-Barr\u00e9 syndrome immunotherapy-a narrative review of new strategies in recent years","volume":"19","author":"Yao","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.3390\/ijms24043073","article-title":"Relationship between hypoxic and immune pathways activation in the progression of Neuroinflammation: role of HIF-1\u03b1 and Th17 cells","volume":"24","author":"Arias","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jneuroim.2009.10.001","article-title":"Conversion of peripheral CD4(+)CD25(\u2212) T cells to CD4(+)CD25(+) regulatory T cells by IFN-gamma in patients with Guillain-Barr\u00e9 syndrome","volume":"217","author":"Huang","year":"2009","journal-title":"J Neuroimmunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2017.01.004","article-title":"Memory B cells in Guillain-Barr\u00e9 syndrome","volume":"305","author":"Wang","year":"2017","journal-title":"J Neuroimmunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"606338","DOI":"10.3389\/fimmu.2020.606338","article-title":"Specific induction of double negative B cells during protective and pathogenic immune responses","volume":"11","author":"Ruschil","year":"2020","journal-title":"Front Immunol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12974-017-0818-5","article-title":"Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy","volume":"14","author":"Maddur","year":"2017","journal-title":"J Neuroinflammation"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/acn3.687","article-title":"IVIg-induced plasmablasts in patients with Guillain-Barr\u00e9 syndrome","volume":"6","author":"Brem","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/cei.12215","article-title":"CD19 as a therapeutic target in a spontaneous autoimmune polyneuropathy","volume":"175","author":"Abraham","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2174\/1570159x14666161213114904","article-title":"Biological drugs in Guillain-Barr\u00e9 syndrome: an update","volume":"15","author":"Motamed-Gorji","year":"2017","journal-title":"Curr Neuropharmacol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jneuroim.2004.09.020","article-title":"Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyradiculoneuropathy","volume":"159","author":"Press","year":"2005","journal-title":"J Neuroimmunol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.03.019","article-title":"Increased plasmacytoid dendritic cells in Guillain-Barr\u00e9 syndrome","volume":"283","author":"Wang","year":"2015","journal-title":"J Neuroimmunol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jneuroim.2014.02.002","article-title":"Therapeutic potential of atorvastatin-modified dendritic cells in experimental autoimmune neuritis by decreased Th1\/Th17 cytokines and up-regulated T regulatory cells and NKR-P1(+) cells","volume":"269","author":"Xu","year":"2014","journal-title":"J Neuroimmunol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12974-016-0475-0","article-title":"Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO\/Treg and partly dependent on FasL\/Fas pathway","volume":"13","author":"Li","year":"2016","journal-title":"J Neuroinflammation"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.13764\/j.cnki.lcsy.2023.03.016","article-title":"Changes in immune function in children with variant of Guillain-Barr syndrome Spectrum diseases","volume":"24","author":"Xiao-lan","year":"2023","journal-title":"Practical Clin Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"5862","DOI":"10.1038\/s41598-023-32427-5","article-title":"Single-cell analysis reveals novel clonally expanded monocytes associated with IL1\u03b2-IL1R2 pair in acute inflammatory demyelinating polyneuropathy","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e14321","DOI":"10.1016\/j.heliyon.2023.e14321","article-title":"Neutrophil-to-lymphocyte ratio is a risk indicator of Guillain-Barr\u00e9 syndrome and is associated with severity and short-term prognosis","volume":"9","author":"Sun","year":"2023","journal-title":"Heliyon"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"4286364","DOI":"10.1155\/2018\/4286364","article-title":"Beneficial or harmful role of macrophages in Guillain-Barr\u00e9 syndrome and experimental autoimmune neuritis","volume":"2018","author":"Shen","year":"2018","journal-title":"Mediat Inflamm"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1446472\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T05:10:45Z","timestamp":1731388245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1446472\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":38,"alternative-id":["10.3389\/fneur.2024.1446472"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1446472","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"article-number":"1446472"}}